ORIGINAL RESEARCH article
Front. Oncol.
Sec. Surgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1595553
This article is part of the Research TopicArtificial Intelligence in Clinical Oncology: Enhancements in Tumor ManagementView all 4 articles
Predictive Study of Machine Learning Combined with Serum Neuregulin 4 Levels for Hyperthyroidism in Type II Diabetes Mellitus
Provisionally accepted- Suzhou Ninth People's Hospital, Suzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Neuregulin 4 (NRG4) is a novel metabolic regulator closely associated with insulin resistance and thyroid dysfunction. However, its role in the pathogenesis of comorbid type 2 diabetes mellitus and hyperthyroidism (T2DM-FT) remains to be systematically elucidated. Given the complex clinical characteristics of T2DM-FT patients, traditional statistical methods are often insufficient to effectively analyze nonlinear relationships among multiple variables. Machine learning techniques have garnered widespread attention due to their advantages in modeling high-dimensional, heterogeneous data.Objective: This study was to evaluate the predictive capability of a support vector machine (SVM) model based on serum NRG4 combined with a convolutional neural network (CNN) and long short-term memory network (LSTM)-based ultrasound feature classification (SVM-CNN+LSTM) model for predicting the occurrence of FT in patients with T2DM.Methods: Studied 500 T2DM patients (60 with FT, 440 without), and 200 healthy controls. Collected data on demographics, disease characteristics, NRG4, and thyroid indices. Pearson correlation was used to identify features correlated with NRG4. A parameter-optimized SVM model (C=1, linear kernel) was constructed for structured data modeling. Additionally, a CNN+LSTM network was employed to extract spatial (thyroid morphology) and temporal (hemodynamics) features from ultrasound sequences. These features were then fused with biochemical indicators, such as NRG4, to develop the final SVM-CNN+LSTM multimodal predictive model.Results: Serum NRG4 levels in T2DM+FT patients were significantly higher than those in the healthy Ctrl group (4.44 ± 1.25 vs. 2.17 ± 0.48 μg/L, P < 0.05). NRG4 levels were positively correlated with HOMA-IR (r = 0.593), FT3 (r = 0.773), FT4 (r = 0.683), thyroid volume (r = 0.652), and the resistance index (RI) (r = 0.473) (P < 0.05). The optimized SVM model demonstrated a sensitivity of 86.23%, specificity of 90.33%, and an area under the curve (AUC) of 0.887. In contrast, the fusion model SVM-CNN+LSTM outperformed the SVM model across all metrics, achieving a sensitivity of 91.32%, specificity of 94.18%, and an AUC of 0.943 (P < 0.05).Conclusion: The SVM-CNN+LSTM multimodal model, which integrates serum NRG4 levels with ultrasound features, significantly enhances the predictive accuracy of hyperthyroidism in T2DM patients.
Keywords: SVM, CNN+LSTM model, Nrg4, T2DM complicated by FT, Ultrasound images, Classification
Received: 18 Mar 2025; Accepted: 20 May 2025.
Copyright: © 2025 Gu and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ye Lu, Suzhou Ninth People's Hospital, Suzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.